Vivoryon Therapeutics N.V. Announces Presentations at Forthcoming Conferences
Halle (Saale) / Munich, Germany, November 3, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company dedicated to developing small molecule medicines for inflammatory and fibrotic conditions, primarily focusing on kidney diseases, today reported that the Company’s leadership will attend the following medical and investor events in November:
American Society of Nephrology (ASN) Kidney Week 2025
When: November 5 – 9, 2025
Location: Houston, TX, USA
Title: “The Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Insights from VIVIAD, a Phase 2B Randomized Clinical Study”
Presentation Schedule: Thursday, November 6, 10:00 am – 12:00 pm CST / 5:00 pm – 7:00 pm CET
Session: Late-Breaking Research Posters
Abstract/Poster ID: TH-PO1206
Attendees: Michael Schaeffer, PhD, CBO; Julia Neugebauer, PhD, COO
Conference Link:
One-on-one meetings coinciding with the Jefferies Global Healthcare Conference
When: November 18 – 20, 2025
Location: London, UK
Participants: Frank Weber, MD, CEO; Julia Neugebauer, PhD, COO
To arrange a meeting with the team, please contact:
Deutsches Eigenkapitalforum
When: November 24 – 26, 2025
Location: Frankfurt/M, Germany
Participant: Julia Neugebauer, PhD, COO
Conference Link:
###
Regarding Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company concentrated on advancing innovative small molecule-based medications for the management of inflammatory and fibrotic kidney disorders. Driven by its passion for pioneering science and innovation, the Company strives to enhance patient outcomes by altering the progression of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced initiative, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is currently being assessed for the treatment of diabetic kidney disease.
Vivoryon Forward-Looking Statements
This press release contains forward-looking statements, encompassing, but not limited to, those concerning Vivoryon Therapeutics N.V.’s (the “Company”) business strategy, management intentions, and goals for future operations, as well as market estimates and projections for the Company’s products, and predictions about when these products might become available. Terms such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” along with similar phrases when referring to the Company, are used to identify these forward-looking statements. These statements are not assurances of future achievements; instead, they are grounded in Management’s current beliefs and assumptions regarding upcoming occurrences and trends, the economic climate, and other future circumstances. Forward-looking statements inherently involve various known and unknown risks and uncertainties. These risks, uncertainties, and additional factors could significantly and negatively impact the results and financial repercussions of the plans and events detailed here. The Company’s operational outcomes, capital requirements, financial health, cash flow, future outlook, upcoming dealings, strategies, or occurrences could vary substantially from what is stated or suggested in such forward-looking statements and from current expectations. Consequently, it is advised not to place undue dependence on these forward-looking statements. This press release does not list risk factors. Specific risk factors that might influence the Company’s future financial performance are outlined in its publicly released annual financial statements. This press release, including any forward-looking statements, is valid only as of its publication date. The Company disclaims any responsibility to update any information or forward-looking statements herein, except where legally mandated.
For Further Details, please reach out to:
Investor Relations
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
Email:
Media Relations
Trophic Communications
Valeria Fisher or Verena Schossmann
Phone: +49 175 8041816 / +49 151 219 412 77
Email:
Attachment
